Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.47 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135079 | 1.00 | EPHX2 (0.47) | EPHX2KMT5AUSP2SMN1; SMN2ACKR3 | |
| SCHEMBL28703997 | 0.98 | EPHX2 (0.47) | EPHX2KMT5AUSP2SMN1; SMN2ACKR3 | |
| SCHEMBL16810242 | 0.94 | EPHX2 (0.47) | EPHX2USP2SMN1; SMN2ACKR3TLR8 | |
| SCHEMBL8253901 | 0.91 | USP2 (0.51) | EPHX2KMT5AUSP2SMN1; SMN2ACKR3 | |
| SCHEMBL22262696 | 0.88 | USP2 (0.44) | EPHX2KMT5AUSP2SMN1; SMN2ACKR3 | |
| SCHEMBL15352136 | 0.88 | USP2 (0.44) | EPHX2KMT5AUSP2SMN1; SMN2ACKR3 | |
| SCHEMBL6661328 | 0.88 | USP2 (0.44) | EPHX2KMT5AUSP2SMN1; SMN2ACKR3 | |
| SCHEMBL2225547 | 0.88 | HSD11B1 (0.49) | EPHX2USP2SMN1; SMN2ACKR3TLR8 | |
| SCHEMBL20873847 | 0.86 | USP2 (0.53) | EPHX2USP2SMN1; SMN2ACKR3TLR8 | |
| SCHEMBL1715344 | 0.85 | USP2 (0.46) | EPHX2KMT5AUSP2SMN1; SMN2ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | EPHX2 4789/4885KMT5A 3695/4885USP2 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.